Dec 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Axsome Therapeutics, Ducommun and Vacasa on Tuesday.
HIGHLIGHTS
* Axsome Therapeutics Inc AXSM.O: Needham raises target price to $133 from $130 |
* Ducommun Inc DCO.N: RBC reinstates coverage with outperform rating |
* Vacasa Inc VCSA.O: Needham cuts to hold from buy |
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.
* Axsome Therapeutics Inc AXSM.O: Needham raises target price to $133 from $130 |
* Axsome Therapeutics Inc AXSM.O: RBC raises target price to $138 from $132 |
* Cal-Maine Foods Inc CALM.O: Stephens raises target price to $88 from $82 |
* Ducommun Inc DCO.N: RBC reinstates coverage with outperform rating |
* Ducommun Inc DCO.N: RBC reinstates coverage with price target $72 vs $60 |
* Marinus Pharmaceuticals Inc MRNS.O: Baird raises target price to $0.55 from $0.50 |
* Vacasa Inc VCSA.O: Needham cuts to hold from buy |
* Verastem Inc VSTM.O: BTIG raises target price to $20 from $13 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。
沒有相關數據
如果下載按鈕點擊無跳轉,請點擊右上角菜單選擇 “在瀏覽器打開”